Epidemiological data
Estimated adult HCV prevalence
Worldwide relative burden of HCV among people who use and inject drugs
HCV Diagnostics
Availability of all the diagnostics
Self-testing
Lab-based Antibody Testing
Antibody Rapid Testing
Viral load (NAT/PCR viral load testing)
Core Antigen (HCV core antigen testing)
Liver Staging All Tests
FibroScan
APRI
FIB-4
Other
Genotyping
Dried Blood Spot
HCV Treatment
DAA registration
DAA registration: showcasing status for generics
DAA registration: showcasing status for branded DAAs
DAA registration in PEPFAR countries
DAA registration in Global Fund countries
Gilead Voluntary Licenses
AbbVie Voluntary Licenses
HCV Policy
Countries with hepatitis plans
Operational Needle and syringe programs in general
Operational Needle and syringe programs in prisons
Operational programs for Medication for Opioid Agonistic Therapy (OAT) in general
Operational programs for Opioid Agonistic Therapy (OAT) in prisons
Fibrosis-based treatment restrictions
Abstinence-based treatment restrictions
+
−
Worldwide relative burden of HCV among people who use and inject drugs
0%
97.1%
